The magnitude of antinociception elicited by intrathecal endomorphin 2 (EM2), an endogenous mu-opioid receptor (MOR) ligand, varies across the rat estrous cycle. We now report that phasic changes in analgesic responsiveness to spinal EM2 result from plastic interactions within a novel membrane-bound oligomer containing estrogen receptors (mERs), aromatase (aka estrogen synthase), metabotropic glutamate receptor 1 (mGluR 1 ), and MOR. During diestrus, spinal mERs, activated by locally synthesized estrogens, act with mGluR 1 to suppress spinal EM2/MOR antinociception. The emergence of robust spinal EM2 antinociception during proestrus results from the loss of mER-mGluR 1 suppression, a consequence of altered interactions within the oligomer. The chemical pairing of aromatase with mERs within the oligomer containing MOR and mGluR 1 allows estrogens to function as intracellular messengers whose synthesis and actions are confined to the same signaling oligomer. This form of estrogenic signaling, which we term "oligocrine," enables discrete, highly compartmentalized estrogen/mER-mGluR 1 signaling to regulate MORmediated antinociception induced by EM2. Finally, spinal neurons were observed not only to coexpress MOR, mERa, aromatase, and mGluR 1 but also be apposed by EM2 varicosities. This suggests that modulation of spinal analgesic responsiveness to exogenous EM2 likely reflects changes in its endogenous analgesic activity. Analogous suppression of spinal EM2 antinociception in women (eg, around menses, comparable with diestrus in rats) as well as the (pathological) inability to transition out of that suppressed state at other menstrual cycle stages could underlie, at least in part, the much greater prevalence and severity of chronic pain in women than men.
Introduction
In humans and laboratory animals, nociception/opioid antinociception is sexually dimorphic and varies over the reproductive cycle. 22, 30, 31, 41, 63, 75, 96 We previously reported 63 that male and female rats differ in their responses to the highly selective endogenous m-opioid receptor (MOR) ligand endomorphin 2 (EM2), the predominant endomorphin in the spinal cord. 68, 103 A striking feature of this sexual dimorphism is that the antinociceptive effectiveness of intrathecal (i.t.) EM2 is synchronized with the estrous cycle: the spinal EM2 antinociceptive system alternates between analgesically active and inactive states. 63 Interestingly, this characteristic is not manifested by other MOR ligands, eg, sufentanil ]-enkephalin (DAMGO), 63 consistent with reports that EM2 stimulates specific MOR-coupled signaling pathways that differ from those activated by sufentanil or DAMGO. 63, 72, 84 Paradoxically, spinal EM2 analgesic responsiveness is robust (comparable to males) during proestrus and minimal during diestrus, notwithstanding that circulating levels of estrogens are low during diestrus (more comparable with males) and highest during proestrus. 1, 14, 20, 38, 93, 95 Notably, in female rats, 17-b-estradiol (estradiol), the predominant estrogen, can be pronociceptive, 12, 43, 44, 60, 65, 87 as well as antinociceptive. 4, 15, 32, 34, 50, 55, 66, 83, 88 Modulation of nociception/ opioid antinociception by estrogens occurs, in part, via classic nuclear estrogen receptors (ERs), which function as estrogenactivated transcription factors. 21 However, estrogenic modulation of nociception/opioid antinociception can also occur via ERs (a and b) that traffic to the plasma membrane (mER) 80 subsequent to being palmitoylated. 59 GPR30, a G protein-coupled ER 10, 16, 28, 94 also transduces membrane estrogen signaling. 29, 82 mERs localize to caveolae, where they activate multiple signaling cascades. 73, 74, 98, 99 In addition to differing in their subcellular localization (plasma membrane vs nucleus) and their physiological consequences (activation of second messengers/signaling cascades vs activation of transcription), mERs and nuclear ERs differ in their temporal profile of action (s/min vs h/d, respectively, for the onset and offset of effects).
Since estradiol can both positively and negatively modulate nociception/opioid antinociception, the apparent linkage of spinal EM2 analgesic responsiveness with stage of estrous cycle could result from either (1) enhanced facilitation by estrogen of spinal EM2/MOR antinociception (which, based on circulating levels of estrogens, would be expected to be greater in proestrus than diestrus), (2) a switch in estrogenic modulation from inhibitory in diestrus to facilitative during proestrus, or (3) loss during proestrus of the diestrusassociated negative estrogenic modulation. In order to investigate the nature of the physiological modulation of spinal EM2 antinociception by estrogens, we determined the effects of acutely manipulating spinal estrogenic tone during diestrus and proestrus on spinal EM2 analgesic responsiveness.
Paradoxically, our findings revealed a striking inverse relationship between estrogenic inhibition of spinal EM2 analgesic responsiveness and circulating levels of estrogens. This results from stage of estrous cycle-dependent interactions among components of a novel signaling oligomer. The oligomerization of aromatase with the plasma membrane-associated signaling receptors ERa, MOR, and metabotropic glutamate receptor 1 (mGluR 1 ) provides a novel biochemical framework for estrogenic influences on nociception that can be regulated independent of ovarian production of estrogens.
Methods

Experimental animals
We used female rats (Sprague-Dawley; Charles River, Kingston, NY; 225-275 g), which were maintained in an approved controlled environment on a 12-hour light/dark cycle. Food and water were available ad libitum. All experimental procedures were reviewed and approved by the Animal Care and Use Committee of State University of New York Downstate Medical Center.
Determination of estrous cycle stage
Histology of vaginal smears was used to determine the stage of estrous cycle presurgery as well as postsurgery. Predominance of small leukocytes was indicative of diestrus; predominance of large round nucleated cells indicated proestrus.
Implantation of intrathecal cannula
A permanent indwelling cannula was inserted into the lumbar spinal cord subarachnoid space under isoflurane anesthesia. In brief, a saline-filled catheter (PE-10) was inserted through an incision in the atlanto-occipital membrane, slowly introduced into the spinal cord subarachnoid space (8.0 cm), and secured in place. The cephalic portion of the catheter was externalized through the skin above the skull area, where it was relatively inaccessible to the paws. Only animals that appeared to be free of infection upon gross inspection were used. Motor integrity was assessed in all experimental groups by using the righting reflex and the inclined plane test. Those exhibiting any motor impairment following surgery were eliminated from the study. Experiments were initiated as early as 1 week after surgery and completed within 2 weeks thereafter. In order to eliminate any possibility that surgery confounded data interpretation by disrupting the estrous cycle, diestrus and proestrus were defined by vaginal smear histology, rather than predictions that assumed regularity of cycling. 1 antagonist), and 6-amino-N-cyclohexyl-N,3-dimethylthiazolo [3,2-a] benzimidazole-2-carboxamide hydrochloride (LY341495, an mGluR 2/3 antagonist) were each prepared in 3 mL dimethyl sulfoxide; EM2 was prepared in 5 mL 3% dimethyl sulfoxide. All drugs were obtained from Tocris (Ellisville, MO), except for fadrozole, which was obtained from Sigma (St Louis, MO). Drugs were applied to the spinal cord subarachnoid space over a 60-second period via the indwelling i.t. cannula. Complete delivery was ensured by flushing the cannula with an additional 10 mL of saline. I.t. doses of ER antagonists and fadrozole were based on our previous studies and chosen to maximize targeted effects while minimizing off-target actions. 62 Doses of mGluR 1 and mGluR 2/3 antagonists were based on prior studies, 19, 33, 48, 49, 97, 102, 107 as was the dose of EM2. 63, 101 In order to demonstrate involvement of rapid signaling mERa, we administered i.t. EM2 as early as 5 min after i.t. MPP. In all subsequent experiments, in order to minimize possible confounds resulting from effects of accumulating volumes of i.t. injectate, we applied i.t. EM2 30 minutes following blockade of ERa, ERb, GPR30, or mGluRs. In order to allow for run-down of spinal pools of estrogens, inhibition of spinal aromatase was started 1 hour prior the administration of EM2, as we performed in an earlier study. 62 Importantly, a number of studies have indicated the absence of significant supraspinal diffusion/effects of i.t. injectate even 60 minutes following i.t. injection. 
Assessment of tail-flick latency
Nociceptive response thresholds were assessed using radiant heat as the nociceptive stimulus. Tail-flick latency (TFL) was quantified using a Tail-Flick Analgesia Meter (IITC, Woodland Hills, CA). Intensity of the radiant heat was adjusted such that baseline TFL was in the range of 3.0 to 4.5 seconds. A cutoff of 10-second latency prevented any untoward consequences to the tail. Data are expressed as either absolute TFL or percent change.
Membrane preparation, immunoprecipitation, and western blot analysis
Spinal cord membranes were prepared and solubilized as described previously by this laboratory. 17 Briefly, animals were sacrificed by decapitation; spinal tissue was homogenized in cold 20 mM HEPES, pH 7.4, containing 10% sucrose, 5 mM EDTA, 1 mM EGTA, 2 mM dithiothreitol, and multiple protease inhibitors (1 mM benzamidine, 0.2 g/L bacitracin, 2 mg/L aprotinin, 3.2 mg/ L each of leupeptin and trypsin inhibitor from soybean; 20 mg/L each of N-tosyl-L-phenylalanine chloromethyl ketone, Na-ptosyl-L-lysine chloromethyl ketone and phenylmethylsulfonyl fluoride, and cOmplete cocktail protease inhibitor tablet/50 mL [Roche Molecular Biochemicals, Indianapolis, IN]; for experiments assessing the phosphorylated state of ERa, PhosSTOP cocktail phosphatase inhibitor tablet/10 mL [Roche] was also added). Supernatants from a low-speed spin (1000g for 10 minutes, 4˚C) were centrifuged at a higher speed (30,000g for 40 minutes, 4˚C) to obtain (crude) membrane pellets. Membranes were solubilized in the above buffer without sucrose and dithiothreitol but now containing 150 mM NaCl, 1% Nonidet P-40 (NP-40), 0.5% Na-deoxycholate, 0.1% Na-dodecyl sulfate, and 10% glycerol, agitated for 60 minutes at 4˚C and centrifuged (16,000g for 40 minutes at 4˚C). IPs were obtained from the clear supernatant by overnight incubation (4˚C) of equivalent membrane protein (measured by Bradford assay) with specific antibodies and Protein A or G agarose beads. Immunoprecipitation samples were washed, eluted with heat in sodium dodecyl sulfate sample buffer, separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto nitrocellulose membrane, and Western blotted.
Co-immunoprecipitates (co-IPs) to be compared were always obtained and processed in parallel. Western quantification of the co-immunoprecipitated (co-IPed) protein was always normalized against the protein targeted for direct IP, which was also quantified by Western analysis using antibodies against a different epitope. Moreover, Westerns of all IPed proteins (those directly targeted as well as co-IPed) utilized antibodies raised in a host different from that used for the generation of antibodies used for IP to avoid cross-recognition by secondary antibodies. Antibodysubstrate complex was visualized using Supersignal West Dura kit (Pierce) . Chemiluminescence was captured via G:Box CCD camera (Syngene, Frederick, MD), and intensities were quantified using Genetools software (Syngene).
Specificity of all Western signals (that of the directly IPed as well as co-IPed proteins) was validated by their absence when Western blotting using preadsorbed antibody: antigenic peptide used for generation of the antibody was diluted in 20 mM HEPES, pH 7.4, at 5 times excess to antibody, and covalently coupled to Affi-Gel 10 Gel matrix in accordance with the manufacturer's instructions (Bio-Rad). The desired antibody was added in tris-buffered saline (TBS) and allowed to preadsorb. Following incubation, the flow-through was collected ("preadsorbed antibody") and used to probe one of 2 identical nitrocellulose membrane strips containing the protein of interest (the other strip was probed in parallel with an equivalent amount of primary antibody, and the difference in signal intensity was quantified). The specificity of the phosphoSer118 ERa (pSERa) Western signal was validated by the ability of the anti-pSERaantibody to recognize the 11 aa phosphoSer118 antigenic peptide, but not its nonphosphorylated congener.
Blue native PAGE/SDS-PAGE and sequential immunoprecipitation
Spinal membranes were solubilized in 20 mM HEPES buffer, pH 7.4, containing 1 mM EDTA, protease inhibitors as above, and 2% mild detergent digitonin, incubated on ice (60 minutes) and centrifuged (15,000g, 20 minutes, 4˚C). Native sample buffer and the anionic dye Coomassie Blue G-250 were added to spinal membrane supernatant and electrophoresed using 3% to 12% blue native gels (Invitrogen). Blue native PAGE was carried out as previously described. 89 The migration distances of individual bands relative to marker proteins were used to estimate native masses of membrane proteins. A 360-kDa band was initially identified with Western analysis using either anti-MOR or antiERa antibodies. In subsequent experiments, a band of comparable molecular mass was stained with Coomassie Blue and excised. Native proteins were eluted with 50 mM Tris-HCl containing 150 mM NaCl and 0.1 mM EDTA; pH 7.5. Eluted proteins were separated using SDS-PAGE and immunoblotted for aromatase, ERa, MOR, and mGluR 1 .
For sequential IP, supernatants containing known protein concentrations (Bradford) were subjected to IP utilizing (in order) antibodies against aromatase, ERa, and mGluR 1a . Samples were incubated with antibody cross-linked to Protein A or G agarose beads using DSS (Pierce), washed and gently eluted with 100 mM glycine, pH 2.5. Eluate was neutralized (1 M Tris, pH 8.8) and incubated with the next antibody. The final IP was eluted with 100 mM glycine. Native sample buffer and Coomassie Blue were added to eluted final IP, which was followed by electrophoresis using 3% to 12% blue native gels and electrotransfer onto polyvinylidene difluoride membranes. Anti-MOR Western analysis was performed as reported. 17 Since we had previously demonstrated the specificity of MOR Western signals in spinal cord, 17, 64 this control was not repeated in this study.
Immunocytochemistry
Diestrous female rats were deeply anesthetized with a mixture of ketamine (68 mg/kg), xylazine (4.6 mg/kg), and acepromazine (0.9 mg/kg) and perfused through the ascending aorta with 100 mL of ice-cold oxygenated calcium-free Tyrode's buffer (115 mM NaCl, 5 mM KCl, 2 mM MgCl 2 ·6H 2 O, 400 mM MgSO 4 ·H 2 O, 3 mM glucose, and 25 mM NaHCO 3 , pH 7.2) followed by 500 mL of freshly prepared fixative (4% wt/vol paraformaldehyde, 14% vol/vol saturated aqueous picric acid, 75 mM KH 2 PO 4 , and 85 mM Na 2 HPO 4 ·7H 2 O, pH 6.9). After fixation, the entire vertebral column, including the pelvis, was harvested, placed in cryoprotectant solution (15 mM sucrose, 30 mM K 2 HPO 4 , and 70 mM Na 2 HPO 4 ·H 2 O, pH 7.2), and shipped via overnight air courier service to Minnesota on refrigerant gel packs.
Upon arrival, tissue was dissected quickly, frozen, and serial sections were cut to a nominal thickness of 5 mm on a cryostat (Bright Instruments, Huntington, United Kingdom), thawed on Probe-On Plus microscope slides (Fisher Scientific, Pittsburgh, PA), and stored at 220˚C until used. Sections were rinsed in distilled water and immersed in 10 mM trisodium citrate, pH 6.0, containing 0.05% Tween-20 and autoclaved at 101˚C for 30 minutes. The sections were allowed to cool to room temperature, rinsed in TBS (135 mM NaCl, 4 mM KCl, and 25 mM Tris-HCl, pH 7.4), then incubated in permeabilization solution (TBS containing 0.2% Triton X-100 and 0.2% Tween-20) for 1 hour at room temperature. Sections were incubated with guinea pig anti-MOR 1 , mouse antimGluR 1, and either rabbit anti-ERa, rabbit anti-EM2, or rabbit antiaromatase. All staining with the MOR antibody was abolished when used on MOR knockout mice (not shown). For anti-ERa, the staining specificity was previously validated by confirming immunohistochemical results with a second anti-ERa antibody generated against a different epitope 91 and by preadsorption. 106 Staining specificity of our anti-EM2 antibody in rat has been previously demonstrated. 79 Notably, although EM2 has an amidated Cterminal phenylalanine, which is found in other peptides such as NPFF, this is not sufficient for their detection in tissue by the anti-EM2 antibody employed in this study. 79 Moreover, it is highly unlikely that EM2 staining results from the antibody recognizing either substance P or calcitonin gene-related peptide, given that the antibody does not detect EM2-ir in the lateral spinal nucleus, 79 where substance P is expressed, 36 or in ventral horn motor neurons, where calcitonin gene-related peptide is expressed. 35 Sections were washed and then incubated in a mixture of 3 mg/mL each of donkey anti-rabbit IgG conjugated to Cy3, donkey anti-guinea pig IgG conjugated to Cy2, and donkey antimouse IgG conjugated to Cy5 (Jackson ImmunoResearch). The sections were washed, dehydrated, cleared in xylene, and mounted with coverslips using the permanent, resin-based mounting medium DPX (Fluka, Ronkonkoma, NY).
Microscopy
Images were collected using an Olympus Fluoview 1000 confocal microscope equipped for excitation at 488 nm (Cy2), 543 nm (Cy3), and 635 nm (Cy5). Images were collected with 403 1.3 NA or 603 1.4 NA objectives and pixel dimensions of 0.32 mm or smaller; all images were made using sequential scanning to avoid bleed-through. Photoshop was used to pseudocolor images and to adjust brightness and contrast.
Antibodies
The following antibodies were used for (1) IP: anti-mGluR 1 (sc-47,131; 2 mg per 800 mg of total protein), anti-ERa (sc-71,064; 3 mg per 800 mg of total protein), and anti-aromatase (sc-14,245; 3 mg per 800 mg of total protein), all purchased from Santa Cruz Biotechnology (SCB); (2) Western blot: anti-mGluR 1 (US Biologicals, M3884-75C; 1:1000), anti-ERa (SCB, sc-542; 1:250), anti-aromatase (abcam, ab124776; 1:40,000), anti-GPR30 (SCB, sc-48,524-R; 1:250), anti-MOR (raised in rabbit against carboxyl-terminal 50 aa of MOR; generous gift from Dr Thomas Cote; 1:1000), 18 and anti-pSERa (SCB, sc-12,915-R; 1:250); and (3) immunocytochemistry (ICC): anti-ERa (SCB, sc-542; 1: 1000), 62 anti-MOR 1 (raised in guinea pig against aa 384-398 of MOR 1 ; 1:1000), 5 anti-mGluR 1 (BD Biosciences, 610,964; 1: 1000), anti-aromatase (abcam, ab69653; 1:1000), 13 and anti-EM2 (generated by the Wessendorf laboratory against the full sequence of EM2 and affinity isolated; 1:1000).
78,79
Data analysis and statistics
One-way analysis of variance (ANOVA) was used to compare basal TFL among groups as well as to compare treatment effect within a group; 2-way ANOVA was used to compare either treatment-by-time effects (within the same cycle stage) or cycle stage-by-treatment effects (at 5 minutes after i.t. EM2) on TFL. Unpaired Student t tests were used to analyze differences in Western signals of co-IPed proteins during diestrus vs proestrus. Statistical comparisons were made using Prism 5 software.
Results
Spinal mER-coupled regulation of i.t. EM2 antinociception depends on stage of estrous cycle
Consistent with our earlier report, 63 basal TFL did not significantly vary among groups. Additionally, we replicated our earlier finding that i.t. EM2 produces a significant dose-dependent antinociception during proestrus, whereas during diestrus minimal or no antinociception was observed. 63 Since peak antinociception was observed at 45 nmol i.t. EM2, 63 this dose was used in the current study.
Current data analyses revealed a significant difference in treatment effect (blockade of individual mERs) on spinal EM2 (45 nmol) antinociception during diestrus, but not proestrus ( Fig. 2A vs Fig. 1 ). During proestrus, neither blockade of spinal ERa (via i.t. MPP, 10 nmol, n 5 6), ERb (via i.t. PHTPP, 10 nmol, n 5 4) nor GPR30 (via i.t. G-15, 10 nmol, n 5 4) altered spinal analgesic responsiveness to EM2; two-way ANOVA revealed a significant within-group analgesic effect of EM2 (F 4,68 5 17.03, P , 0.0001) but no effect of treatment (ER blockade; Fig. 2A) . Importantly, the effect of MPP was manifest as early as 5 minutes after its spinal pretreatment (F 1,18 5 6.21, P , 0.05 for the comparison between MPP1EM2 group vs DMSO1EM2 group, n 5 4; Fig. 2A inset) , suggesting the relevance of rapid mER signaling to spinal EM2 antinociception. Pretreatment with MPP or G-15 in the absence of EM2 (but in the presence of its vehicle) did not alter TFL (MPP: F 4,12 5 0.047, P 5 0.75; G-15: F 4,12 5 1.944, P 5 0.17; n 5 4 for both drugs; Fig. 2A) . Moreover, the spinal EM2 antinociception (5 minutes after i.t. EM2) in MPP or G-15 pretreated diestrous rats was indistinguishable not only between these 2 groups (F 1,32 5 0.009, P 5 0.926) but also from the vehiclepretreated proestrous group (F 2,28 5 0.092, P 5 0.913; Fig. 2A vs Fig. 1 ). These results indicate that the transition from being unresponsive to i.t. EM2 to being analgesically responsive to it did not result from a qualitative shift in estrogenic modulation, but instead involved the loss of its negative modulation.
During proestrus, 15 nmol EM2 failed to elicit significant antinociception (F 4,16 5 2.71, P 5 0.068), whereas antinociception was elicited by both 45 (F 4,28 5 5.64, P 5 0.002) and 90 nmol (F 4,16 5 4.47, P 5 0.013). These responses were indistinguishable (F 1,44 5 1.00, P 5 0.339), suggesting that 45 nmol produced maximum antinociception. Notably, in diestrus, antinociceptive responses to i.t. EM2 following i.t. MPP were comparable to those observed in untreated proestrous rats. In diestrous rats pretreated with i.t. MPP, 15 nmol EM2 continued to be below threshold (F 4,12 5 0.91, P 5 0.447) and 45 nmol produced an antinociception (F 4,12 5 10.61, P , 0.001), the magnitude of which did not differ from that observed in proestrous rats (F 1,40 5 0.082, P 5 0.781) (Fig. 2B) .
In contrast to ERa or GPR30 blockade, blockade of ERb (via i. 
Locally synthesized estrogens regulate spinal EM2 analgesia
To determine if spinal ER-mediated suppression of i.t. EM2 antinociception requires locally synthesized estrogens, we investigated the effect of the intrathecally applied aromatase inhibitor fadrozole (2.5 nmol) (Fig. 2C) . In diestrus, i.t. application of fadrozole (1 hour pretreatment) unveiled a robust spinal EM2
test: P , 0.01 for basal TFL vs TFL at 5 minutes following i.t. EM2), comparable in magnitude to the EM2 antinociception observed in proestrous rats (shown in Fig. 1 ) (F 1, 20 5 0.481, P 5 0.496). Importantly, the same i.t. fadrozole pretreatment in the absence of i.t. EM2 (but in the presence of its vehicle) did not alter TFL (F 4,12 5 2.45, P 5 0.103, n 5 4; Fig. 2C ). Since blockade of spinal ERs did not alter i.t. EM2 antinociception in proestrous rats (Fig. 1) , the effect of i.t. fadrozole on spinal EM2 antinociception was not determined at this estrous stage.
Association of spinal aromatase with mERa and GPR30
The specific stage of the estrous cycle when spinal aromatase/ mERa activity is physiologically relevant varies for different endpoints. For example, spinal aromatase/mERa activity is essential for the heterodimerization of MOR with KOR during proestrus, 62 but during this cycle stage, spinal aromatase/mERa activity does not modulate spinal EM2 antinociception (although it does during diestrus). These differences imply that discrete populations of spinal mERa are independently activated by discrete pools of locally synthesized estrogens. The most parsimonious model to explain segregated activation of spinal mERa is one that posits its presence in spatially and functionally segregated plasma membrane-associated complexes with aromatase.
To test this hypothesis, we determined if spinal aromatase and mERa co-IP. The magnitude of aromatase IPed from spinal cords of diestrous vs proestrous rats did not differ. Two previously reported molecular mass species of ERa (35 and 50 kDa) 9, 57, 104 were present in aromatase IP obtained from spinal membranes of both diestrous and proestrous rats (Fig. 3A, left panel, data shown only for diestrus). The magnitude of the co-IP of mERa with aromatase was not dependent on stage of estrous cycle, ie, the signal intensity of neither the 35-nor the 50-kDa ERa species differed between diestrous vs proestrous rats (n 5 7; unpaired t test: P . 0.05 for both comparisons, data not shown). These results indicate that aromatase and mERa are physically associated, and their association does not vary over the estrous cycle. In order to ascertain if the association of aromatase with spinal mERa generalizes to GPR30, we also explored the presence of GPR30 in spinal aromatase IP. When aromatase IP was Western blotted with anti-GPR30 antibody, a signal was observed at 50 kDa (Fig. 3A, right panel; data shown only for diestrus), the reported molecular mass for GPR30. 108 We did not explore the co-IP of aromatase with mERb, since activity of this ER did not suppress i.t. EM2 antinociception during diestrus.
Aromatase-mERa complexes are functional units, varying in activity during diestrus vs proestrus
ERa is phosphorylated in response to estrogens, predominantly on Ser118, which increases its activity. 45, 54 The rapidity (,5 minutes) of phosphoSer118 ERa (pSERa) formation implies that it is a direct response to estrogen binding. 45 Thus, the content of pSERa in aromatase IP reflects the activation of the co-IPed mERa. This, in turn, indicates elevated production of local estrogens, and thus the increased activity of mERa-associated aromatase. Accordingly, we quantified by Western analysis the co-IP of membrane pSERa with aromatase. Two molecular mass species of pSERa (35 and 50 kDa) were observed (Fig. 4A) . The mean signal intensity of both pSERa Western signals was significantly elevated in diestrous vs proestrous rats (P , 0.05, n 5 6; 32% and 50% for upper and lower bands, respectively; Fig.  4B ). These results indicate that the activity of the mERa that is complexed with spinal aromatase (and presumably the activity of that aromatase), is elevated during diestrus, ie, is inversely related to circulating levels of estrogens. Fig. 5 ).
mGluR
Association of mERa and mGluR 1 is augmented in spinal cord of diestrous vs proestrous rats
ERs interact with and activate membrane receptors (eg, epidermal growth factor receptor and insulin-like growth factor-1 receptor 47, 81 ). We hypothesized that mERa activates mGluR 1 via analogous protein-protein interactions. The ability of mGluR 1 to be activated by mERa would thus be reflected by their co-IP. Accordingly, to determine whether spinal mERa-mGluR 1 signaling varied between diestrus and proestrus, we compared the presence of mERa in mGluR 1 IP obtained from spinal membranes of diestrous and proestrous rats. Two molecular mass species of mERa, comparable to those present in aromatase IP (50 and 35 kDa), were present in mGluR 1 IP (Fig. 6A) . Interestingly, the content of both species of mERa was significantly elevated in diestrous vs proestrous rats (50 kDa: 42%, P 5 0.027; 35 kDa: 54%, P 5 0.008; n 5 6; Fig. 6B ). This is consistent with mERamGluR 1 negative modulation of spinal EM2 analgesic responsiveness during diestrus, but not proestrus. Fig. 3 , was Western blotted using an antibody selective for phosphoSer118 ERa (pSERa). (B) Bar graph shows quantification of differences in signal intensity of the 35-and 50-kDa pSERa molecular mass species normalized with respect to IPed aromatase. The augmented signal intensity of pSERa in diestrus, indicating increased ERa activation, likely reflects increased activity of the associated aromatase during diestrus. *P , 0.05 for comparison of co-IPed pSERa from spinal cord of D (diestrous) vs P (proestrous) rats. (C) Specificity of anti-pSERa antibody. The antigen used to generate the antibody against pSERa (pS-pep) and its nonphosphorylated congener (non-pS-pep) (11 aa surrounding Ser118; 2 mg each) were Western blotted using anti-pSERa antibody. Whereas a Western signal was obtained when blotting the phosphorylated antigenic peptide, no signal was obtained when blotting its nonphosphorylated congener. Aro, aromatase; WB, Western blot. 
Presence of an oligomer containing MOR, mERa, mGluR 1 , and aromatase in spinal cord
The co-IP of aromatase with mERa, and mERa with mGluR 1 , as well as the ability of mERa-mGluR 1 signaling to negatively modulate i.t. EM2 antinociception, suggests the close physical association of aromatase, mERa, mGluR 1 , and MOR. To investigate this possibility, spinal membranes were electrophoresed using blue native gels. The 360-kDa band that was initially immunostained with either anti-MOR or anti-ERa antibodies and in subsequent experiments identified using Coomassie Blue was excised and eluted. Equal aliquots of the eluted band were subjected to reducing SDS-PAGE. Western analyses employing antibody against aromatase, ERa, mGluR 1 , or MOR revealed that all were contained in the 360-kDa band that was visualized using native gel electrophoresis (Fig. 7A, B) .
The apparent molecular mass of the ERa present in the 360-kDa oligomer (60 kDa) differed from the low molecular mass isoforms that associate with either mGluR 1 or aromatase (50 kDa and 35 kDa, the latter being the one that was predominantly phosphorylated during diestrus). Isoform-specific associations observed for mERa are paralleled by variation in apparent molecular mass of MORs; whereas the 50-kDa species of MOR is present in the oligomer (Fig. 7) , the 60-kDa MOR species predominantly heterodimerizes with KORs. 17 Notably, the 50-kDa MOR species is a minor fraction of MORs present in spinal cord, the predominant molecular mass species being 60 and 75 kDa (data not shown and Refs. 56, 105) . This suggests that variation in the degree of N-linked terminal glycosylation of MOR (the most likely explanation for varying molecular mass) could influence its chemical partnering. Taken together, these observations indicate that biochemical context can be an important determinant of the relative participation/ subcellular sorting of the different molecular mass species of a particular protein, and thus functional differences among them.
To validate that aromatase, mERa, mGluR 1 , and MOR were indeed present in a common oligomer and not different complexes that comigrated on native gels, we performed sequential IP using (in order) antibody against aromatase, ERa, and mGluR 1 . The final IP was eluted, electrophoresed using blue native gels, and Western blotted with anti-MOR antibody, which revealed a 360-kDa band. This cross-validated the presence of a 360-kDa oligomer in spinal cord containing aromatase, mERa, mGluR 1 , and MOR (Fig. 7C) . Importantly, the presence of aromatase in a complex containing MOR and mGluR 1 , which overwhelmingly localize to the plasma membrane, underscores the similar location of aromatase (and thus, the likely production of estrogens) despite the possible presence of microsomes in our crude membrane preparations.
Coexpression of MOR, mGluR 1 , ERa, and aromatase in spinal neurons apposed by EM2 varicosities
If endogenous EM2 acts at least in part via cells expressing an oligomer of aromatase, mERa, mGluR 1 , and MOR, there should exist at least some spinal neurons that coexpress these proteins and are apposed by EM2 varicosities. Although aromatase, mERa, mGluR 1 , and MOR are distributed broadly in the dorsal horn, Figure 8A (top panels) shows that these signaling molecules are sometimes coexpressed in or near the plasma membrane of neurons in the superficial dorsal horn during diestrus. Endomorphin 2 is also widely distributed in the dorsal horn, frequently not apposed to MOR, as previously reported. [67] [68] [69] 78, 79 This is consistent with reports that EM2 interacts with MOR via nonsynaptic mechanisms.
2,92 Figure 6 . Association of spinal mERa and mGluR 1 is greater during diestrus than proestrus. IP was obtained from solubilized spinal membranes of diestrous and proestrous rats using anti-mGluR 1 antibody. mERa present in mGluR 1 IP was assessed via Western analysis using anti-ERa antibody. (A) mGluR 1 IP contained 35-and 50-kDa species of ERa. (B) Bar graph shows quantification of differences in signal intensity of each molecular mass species, normalized with IPed mGluR 1 . The content of both ERa species (mean 6 SEM; n 5 6) was significantly greater in mGluR 1 IP obtained from spinal cord of diestrus vs proestrus rats. *P , 0.05 for comparison of co-IPed ERa from spinal cord of D (diestrous) vs P (proestrous) rats. (C) Specificity of anti-mGluR 1 antibodies. mGluR 1 was IPed from spinal cord using anti mGluR 1 antibody (Å) but not its preadsorbed control (∅). IPs were Western blotted as described in Methods using antibodies generated against an epitope different from that used to generate the IP antibody. The 137-kDa signal visualized in Western blots of mGluR 1 IP using anti-mGluR 1 antibody (1; lane 1) was eliminated when blotting with the preadsorbed antibody (2; lane 2). Lane 3 shows the absence of the Western signal when blotting IP obtained using preadsorbed anti-mGluR 1 IP antibody (∅). WB, Western blot. Nevertheless, Figure 8B (bottom panels) shows an EM2-immunoreactive varicosity apposing the dendrite of a MORimmunoreactive neuron in L6 spinal cord that coexpresses mGluR 1 and mERa. ERa is also abundantly expressed in the cell body as well as in or near the plasma membrane of spinal neurons. These ICC data provide a cellular basis for our proposal that spinal mERa and mGluR 1 interact within a neuron also producing estrogens to negatively modulate i.t. EM2 analgesia during diestrus (Fig. 9 for schematic representation of our hypothesis). Immunocytochemistry images show that MOR, aromatase, mGluR 1 , and mERa largely exist in different parts of the cell. This appears to be at odds with our data pointing to their substantial membrane oligomeric organization, as shown by IP. However, it is important to note that IP and ICC are not quantitatively comparable since (1) the preparation used for IP contains a predominance of plasma membranes vs the other intracellular compartments visible in the ICC images, and (2) immunogenic epitopes within an oligomer may not be as accessible in fixed tissue as they are in the unfixed, solubilized membrane preparation. These considerations could also explain the profound effects of blocking spinal mERa or mGluR 1 on i.t. EM2 antinociception even though many of the MORs appear not to be juxtaposed with mERa or mGluR 1 .
Discussion
This study demonstrates: (1) during diestrus, but not proestrus, spinal antinociceptive responsiveness to i.t. EM2 is actively suppressed by spinal mERa-mGluR 1 signaling; (2) spinally synthesized estrogens are required for this suppression; (3) aromatase, classically considered to be an intrinsic endoplasmic reticulum protein, is present in a spinal plasma membrane oligomer containing mERa, mGluR 1 , and MOR; and (4) MOR-ir neurons in the superficial dorsal horn receiving EM2 input coexpress aromatase, mERa, and mGluR 1 , suggesting the relevance of the above oligomer to endogenous EM2 antinociception.
Estrogenic suppression of i.t. EM2 antinociception likely results from rapid-signaling mERs, since the effect of ERa blockade was manifest as early as 5 minutes following the i.t. pretreatment with MPP, shorter than the approximately 20 minutes required for transcription of even immediate early genes. 53 Moreover, physiological effects of proteins encoded by these genes would require translation, subsequent chemical modification and intracellular trafficking in addition to transcription, which would exceed both the 5-and 30-minute pretreatment times employed. Thus, rapid signaling mERa/GPR30 are the most likely ERs that suppress spinal EM2 analgesic responsiveness.
Inhibition of spinal aromatase during diestrus (via i.t. fadrozole) unmasks i.t. EM2 antinociception, indicating that suppression of spinal EM2 antinociception during diestrus results from spinal ER activation by locally synthesized estrogens. This is consistent with the presence of aromatase in many spinal areas involved in nociception/opioid antinociception. 26, 27, 40, 76, 77 Spinal ERs can also be activated by peripheral estrogens, which penetrate the blood-brain barrier. 37 The contribution of peripheral estrogens to suppression of i.t. EM2 antinociception was not explored in the current study, since it is exceedingly problematic to selectively . Its dendrite, extending to the right, is apposed by 2 EM2-ir varicosities (arrows). Image is a projection of 4 consecutive optical sections (2 mm total distance in the z-axis). Overlay of green and blue produces cyan. Right: The same MOR-ir neuron expresses ERa-ir in or near its plasma membrane (arrows) and within its cell soma. These observations suggest the presence of an anatomical organization in spinal cord that is consistent with our hypothesis that spinal EM2 antinociception results, at least in part, from its innervating spinal neurons that both synthesize and respond to estrogen. Figure 9 . Interactions among components of an oligomer containing aromatase (Aro), mERs, mGluR 1 , and MOR underlie estrous cycle-dependent analgesic responsiveness to i.t. EM2. During diestrus, estrogens (E) synthesized within this oligomer (denoted by the green oval), activate mER/ mGluR 1 signaling, thereby suppressing EM2 antinociception. During proestrus, interactions between mGluR 1 and mERs that suppress EM2 antinociception are lost (denoted by the broken yellow line between mGluR 1 and mER). We envision that this loss results from the physical dissociation of mGluR 1 and mERs, and/or intramolecular rearrangement of oligomer components.
eliminate circulating estrogens without also eliminating other (ovarian) factors: an ovariectomized rat is not an appropriate control for an intact diestrous rat, notwithstanding their comparably low circulating levels of estrogens.
Estrogen activation of mERa is reflected by its phosphorylation. 45, 54 Thus, the significant (albeit modest) increase in membrane pSERa that co-IPed with aromatase from spinal cord of diestrous vs proestrous rats likely reflects an increase in the activity of the aromatase associated with mERa. Importantly, the increase in pSERa we observed is probably an underestimate, since the antibody used to IP aromatase is not selective for its activated form: both nonactivated and activated mERa were coIPed.
The inverse relationship between the activity of at least some populations of spinal aromatase and circulating concentrations of estrogens indicates that cycle stage does not reliably predict the magnitude of spinal estrogenic signaling. At present, mechanisms responsible for this out-of-phase relationship between spinal aromatase activity and circulating levels of estrogens are not known. However, this inverse relationship could underlie inconsistent findings regarding the magnitude of nociception/ opioid antinociception over the estrous and menstrual cycle. 23 Additionally, the differential dependence of the activity of discrete pools of aromatase on stage of cycle could account for variable nociception/opioid antinociception across the reproductive cycle 22, 30, 31, 41, 63, 75, 96 and provides an imperative for including more than a single reproductive cycle stage when studying pain and its amelioration.
In cultured hippocampal pyramidal neurons, estradiol (via mERa) activates mGluR 1 (inducing CREB phosphorylation). 11 Additionally, direct interactions between mERa and mGluR 1 activate MOR in the medial preoptic nucleus. 24 In the current study, it is possible that the i.t. EM2 antinociception unveiled during diestrus by mGluR 1 blockade resulted from the loss of mGluR 1 -mediated hyperalgesia, independent of any association of mGluR 1 with mERs and/or MOR. However, this is unlikely since i.t. application of the mGluR 1 blocker YM298198 alone had no effect on TFL.
The suggested functional association between spinal mERa and mGluR 1 is underscored not only by their co-IP but also by the fact that the loss of mERa-coupled negative modulation of spinal EM2 antinociception during proestrus (reflected by the inability of spinal ERa blockade to increase spinal EM2 antinociception) is accompanied by the diminution of the mERa-mGluR 1 physical association (reflected by their reduced co-IP). We hypothesize that mERa activation is a prerequisite for its interaction with mGluR 1 . In diestrus, increased spinal aromatase activity (resulting in increased estrogen production) and consequent mERa phosphorylation promote mERa's interaction with mGluR 1 . Conversely, in proestrus, reduced spinal aromatase activity and thus reduced mERa phosphorylation promote mERa-mGluR 1 disassociation. Although not tested in this study, it is likely that mGluR 1 also associates with GPR30, given that GPR30 associates with both aromatase (present findings) and mERa. 51 The robust spinal antinociceptive responsiveness to EM2 during proestrus could result from either the loss of mERa-/ GPR30-coupled negative modulation or a shift in mERa/GPR30 modulation from inhibition to facilitation (eg, E2 activation of mERa can both increase and decrease CREB activity in hippocampal neurons 11 ). However, it is unlikely that facilitatory mERa signaling contributes to the emergence of EM2 antinociception during proestrus, since blockade of spinal mERa did not diminish i.t. EM2 antinociception at this cycle stage. Thus, augmented EM2 analgesic responsiveness in proestrus most likely emerges from the loss of diestrus-associated mERa-/ GPR30-coupled suppression.
Three main strategies have been described for estrogen's actions: endocrine, paracrine, and autocrine. These differ only with respect to the distance between the point of synthesis and the site of action (reviewed in 86 ). Recently, a fourth, synaptocrine, has been proposed in the central nervous system (CNS), 86 which involves specific modulation of synaptic estrogen concentrations. Synaptocrine estrogenic signaling is made possible by the presence of aromatase and ERs on dendritic/somatic membranes and presynaptic terminals. [6] [7] [8] 70, 71, 90, 100 The current demonstration of aromatase in membrane preparations, however, does not permit quantitative comparisons with previous studies demonstrating abundant aromatase in the cell body, 25, 42 given differences in preparation and visualization techniques employed: IP concentrates aromatase, and Western blots amplify the corresponding chemiluminescent signal.
Current findings provide an additional dimension of CNS estrogenic signaling. The oligomerization of aromatase and mERs with other plasma membrane-associated signaling molecules confers exquisite spatial and temporal specificity to estrogenic signaling. Furthermore, the presence of aromatase activity within a signaling complex containing mERs permits the activation of discrete subcellular ER-coupled signaling (eg, via mGluR 1 ). We coin the term "oligocrine" to describe the ability of estrogens to function as intracellular messengers that are synthesized and act within the same macromolecular signaling complex. The oligomeric segregation of aromatase-mERs allows the on/off switching of spinal mER signaling to be independent of estrous cycle-associated variations in circulating levels of estrogens-either out of phase (as in the current study) or in-phase with them (eg, spinal mER-mediated facilitation of MOR/KOR heterodimerization 62 ). Central nervous system oligocrine estrogenic signaling would complement endocrine (peripheral estrogens acting on CNS ERs) and neurotransmitter-like synaptocrine estrogenic signaling. The presence of multiple modalities of CNS estrogenic signaling suggests the importance of coordinating not only the actions of peripheral and central estrogens but also the activity of spatially and, presumably, functionally segregated pools of aromatase in the CNS. Coordination of effects of estrogens acting at multiple levels could provide a sophisticated means of modulating a variety of functions, including pain sensitivity.
This study did not directly investigate endogenous spinal EM2 antinociception. However, we expect that current findings likely pertain to regulating endogenous spinal EM2 analgesic functionality, since some spinal neurons coexpressing MOR, mERa, mGluR 1 , and aromatase are apposed by EM2 varicosities. Although the gene encoding endomorphins has not been found, (1) the human proteome contains 2 proteins with the sequence of a Gly-extended EM2 that are flanked by Gly-Ser cleavage sites, 61 (2) Tyr-Pro has been proposed to serve as a biosynthetic precursor for EM, 85 and (3) the presence of EM1/EM2 in the CNS was demonstrated biochemically via Edman degradation and sequencing, independent of antibody recognition. 103 The relevance of current findings to nociception/opioid antinociception in women remains to be established. Notably, the peak severity of many chronic pain conditions predominantly afflicting women (eg, fibromyalgia and migraine) occurs around the time of menses, 39 which is comparable to diestrus in rats. Physiological suppression of endogenous spinal EM2 antinociception at specific menstrual cycle stages and the inability to transition out of that suppressed state could contribute to the greater frequency and severity of chronic pain syndromes in women than men. The mechanisms by which estrogens influence nociception/ opioid antinociception is a gateway to understanding how nociceptive stimuli are processed and modulated in females. The current demonstration that aromatase oligomerizes with mERs and other plasma membrane receptors, enabling spatially restricted activation of mERs to be inversely related to circulating levels of estrogens, can explain why some estrogen-dependent influences on nociception/opioid antinociception are in-phase and others out of phase with ovarian estrogen production. Additionally, our finding that MOR functions within an oligomer containing regulators of its activation could inform the development of novel pharmacotherapies that target interactions among oligomer components not only for chronic pain management (in women) but also for other CNS disorders resulting from impaired estrogenic signaling.
Conclusion
The current study reports a new modality of estrogenic signaling in spinal cord. We show the association of aromatase with the plasma membrane receptors mERa, mGluR 1 , and MOR, allowing estrogens to function as intraneuronal messengers whose synthesis and actions are segregated within a plasma membrane signaling unit that regulates spinal EM2 antinociception. This novel organization of aromatase with mERs explains why some estrogen-dependent functionalities are in-phase and others out of phase with circulating estrogen levels. The reported oligomerization of ERs could inform therapeutic interventions for chronic pain syndromes disproportionately afflicting women.
